SCHEMBL3779640

SCHEMBL3779640

Cc1c(Cc2ccc(F)cc2)c(OC(F)F)nc2c(Cl)ccc(OCC(=O)O)c12

nearest known ligand 0.45

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 2/20 0.45
PLA2G2A P14555 2/20 0.37
PPARD Q03181 7/20 0.37
FFAR1 O14842 1/20 0.37
TSHR P16473 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
PTGDR Q13258 1/20 0.34
PKM P14618 1/20 0.34
RORC P51449 1/20 0.34
THRA P10827 2/20 0.33
THRB P10828 2/20 0.33
EGLN1 Q9GZT9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3777818 0.94 PTGDR2 (0.44) PTGDR2PPARDTSHRTDP1RORC
SCHEMBL3781764 0.93 PTGDR2 (0.40) PTGDR2PLA2G2APPARDFFAR1TSHR
SCHEMBL3671435 0.92 PTGDR2 (0.41) PTGDR2PPARDTSHRTDP1RORC
SCHEMBL3772529 0.91 ALDH1A1 (0.38) PTGDR2PLA2G2A
SCHEMBL3780664 0.91 PTGDR2 (0.54) PTGDR2PLA2G2APPARDFFAR1PTGDR
SCHEMBL533998 0.90 PTGDR2 (0.40) PTGDR2PPARDTSHRTDP1RORC
SCHEMBL3786033 0.89 PTGDR2 (0.40) PTGDR2PTGDRRORC
SCHEMBL2572541 0.89 PTGDR2 (0.39) PTGDR2PPARDTSHRTDP1RORC
SCHEMBL3785469 0.88 PTGDR2 (0.51) PTGDR2PPARDTSHRTDP1
SCHEMBL10331941 0.88 PTGDR2 (0.39) PTGDR2PPARDTSHRTDP1RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928457-B1 QUINOLINES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-12-12 EP disclosed
EP-1928457-B1 QUINOLINES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-12-12 EP disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
EP-1928457-A2 QUINOLINES AND THEIR THERAPEUTIC USE Argenta Discovery Limited (GB) 2008-06-11 EP disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156600-A1 Quinolines and Their Therapeutic Use NR3C1, NR3C2, NR1H3 PTGDR2 146/4885PLA2G2A 1779/4885PPARD 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.